The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
XL t(8;21) plus
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
Several recurrent balanced translocations and inversions, and their variants, are recognized in the WHO category acute myeloid leukemia (AML) with recurrent genetic abnormalities. Furthermore, several cytogenetic abnormalities are considered sufficient to establish the WHO diagnosis of AML with myelodysplasia-related features when 20% or more blood or marrow blasts are present.
The t(8;21)(q21;q22) is the most common translocation in de novo AML occurring in up to 20% of adult and 40% of pediatric cases of AML. The translocation fuses RUNX1 with RUNX1T1 to produce a RUNX1/RUNX1T1 fusion gene located on the derivative chromosome 8. The prognosis after intensive chemotherapy is better for these patients than for the majoritiy of AML patients. Small hidden interstitial insertions resulting in an RUNX1/RUNX1T1 rearrangement have been found, necessitating the use of a breakpoint spanning rather than a breakpoint flanking FISH probe.
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the relevant loci.
- Zhang et al (2002) PNAS 99: 3070-3075
- Gamerdinger et al (2003) Gene Chromosome Canc 36: 261-272
- Jang et al (2010) Ann Clin Lab Sci 40 :80-84